Increased IR in the liver of patients with NAFLD reduces insulin activity and insulin sensitivity, which affects glycemic control in T2DM and participates in the disease progression of its major complications, so the difficulty of glycemic control is also elevated in patients with T2DM with comorbid NAFLD [34]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.